Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, Share, Trends and Forecast 2022-2030

Description

Market Analysis and Insights: Global Alpha 1 Antitrypsin Deficiency Treatment Market
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener's granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

The global Alpha 1 Antitrypsin Deficiency Treatment market size is projected to reach US$ 3425.1 million by 2028, from US$ 1860.6 million in 2021, at a CAGR of 9.0% during 2022-2028.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Alpha 1 Antitrypsin Deficiency Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Alpha 1 Antitrypsin Deficiency Treatment market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Alpha 1 Antitrypsin Deficiency Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Alpha 1 Antitrypsin Deficiency Treatment market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Alpha 1 Antitrypsin Deficiency Treatment market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Other

Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users

COPD

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Pfizer

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Teva Pharmaceutical Industries

Takeda

Baxter

Grifols

CSL Behring

Kamada Ltd

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

TABLE OF CONTENT

1 Report Business Overview
1.1 Study Scope

1.2 Market Analysis by Indication

1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication, 2017 VS 2021 VS 2028

1.2.2 Augmentation Therapy

1.2.3 Cystic Fibrosis(CF)

1.2.4 Non-CF Bronchiectasis(NCFB)

1.2.5 Diabetes

1.2.6 Other

1.3 Market by End Users

1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users, 2017 VS 2021 VS 2028

1.3.2 COPD

1.3.3 Cystic Fibrosis(CF)

1.3.4 Non-CF Bronchiectasis(NCFB)

1.3.5 Diabetes

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2017-2028)

2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region

2.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2017-2022)

2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028)

2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics

2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends

2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers

2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges

2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue

3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2017-2022)

3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2017-2022)

3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue

3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio

3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021

3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served

3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service

3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication

4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2017-2022)

4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028)

5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users

5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2017-2022)

5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028)

6 North America

6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)

6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication

6.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)

6.2.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)

6.2.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)

6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users

6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)

6.3.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)

6.3.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)

6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

6.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)

6.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)

6.4.3 United States

6.4.4 Canada

7 Europe

7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)

7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication

7.2.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)

7.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)

7.2.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)

7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users

7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)

7.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)

7.3.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)

7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

7.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)

7.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)

8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication

8.2.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)

8.2.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)

8.2.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)

8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users

8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)

8.3.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)

8.3.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)

8.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region

8.4.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)

9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication

9.2.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)

9.2.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)

9.2.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)

9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users

9.3.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)

9.3.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)

9.3.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)

9.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

9.4.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)

9.4.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)

10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication

10.2.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)

10.2.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)

10.2.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)

10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users

10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)

10.3.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)

10.3.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)

10.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country

10.4.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.1.5 Pfizer Recent Developments

11.2 GlaxoSmithKline

11.2.1 GlaxoSmithKline Company Details

11.2.2 GlaxoSmithKline Business Overview

11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.2.5 GlaxoSmithKline Recent Developments

11.3 AstraZeneca

11.3.1 AstraZeneca Company Details

11.3.2 AstraZeneca Business Overview

11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.3.5 AstraZeneca Recent Developments

11.4 Boehringer Ingelheim

11.4.1 Boehringer Ingelheim Company Details

11.4.2 Boehringer Ingelheim Business Overview

11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.4.5 Boehringer Ingelheim Recent Developments

11.5 Teva Pharmaceutical Industries

11.5.1 Teva Pharmaceutical Industries Company Details

11.5.2 Teva Pharmaceutical Industries Business Overview

11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.5.5 Teva Pharmaceutical Industries Recent Developments

11.6 Takeda

11.6.1 Takeda Company Details

11.6.2 Takeda Business Overview

11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.6.5 Takeda Recent Developments

11.7 Baxter

11.7.1 Baxter Company Details

11.7.2 Baxter Business Overview

11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.7.5 Baxter Recent Developments

11.8 Grifols

11.8.1 Grifols Company Details

11.8.2 Grifols Business Overview

11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.8.5 Grifols Recent Developments

11.9 CSL Behring

11.9.1 CSL Behring Company Details

11.9.2 CSL Behring Business Overview

11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.9.5 CSL Behring Recent Developments

11.10 Kamada Ltd

11.10.1 Kamada Ltd Company Details

11.10.2 Kamada Ltd Business Overview

11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.10.5 Kamada Ltd Recent Developments

11.11 Chiesi Pharmaceuticals

11.11.1 Chiesi Pharmaceuticals Company Details

11.11.2 Chiesi Pharmaceuticals Business Overview

11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.11.5 Chiesi Pharmaceuticals Recent Developments

11.12 Kedrion Group

11.12.1 Kedrion Group Company Details

11.12.2 Kedrion Group Business Overview

11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.12.5 Kedrion Group Recent Developments

11.13 Vertex Pharmaceuticals

11.13.1 Vertex Pharmaceuticals Company Details

11.13.2 Vertex Pharmaceuticals Business Overview

11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.13.5 Vertex Pharmaceuticals Recent Developments

11.14 ProMetic Life Sciences

11.14.1 ProMetic Life Sciences Company Details

11.14.2 ProMetic Life Sciences Business Overview

11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction

11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)

11.14.5 ProMetic Life Sciences Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

Choose License Type

Checkout Inquiry Sample